Total Payments
$114,099
2024 Payments
$23,222
Companies
14
Transactions
84
Medicare Patients
9,556
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$72,436 (63.5%)
Consulting$19,673 (17.2%)
Research$12,880 (11.3%)
Travel$8,131 (7.1%)
Food & Beverage$824.65 (0.7%)
Education$155.52 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,436 | 31 | 63.5% |
| Consulting Fee | $19,673 | 13 | 17.2% |
| Unspecified | $12,880 | 11 | 11.3% |
| Travel and Lodging | $8,131 | 12 | 7.1% |
| Food and Beverage | $824.65 | 10 | 0.7% |
| Education | $155.52 | 7 | 0.1% |
Payments by Type
General
$101,219
73 transactions
Research
$12,880
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $48,665 | 29 | $0 (2024) |
| PFIZER INC. | $19,017 | 15 | $0 (2024) |
| Lilly USA, LLC | $10,939 | 7 | $0 (2023) |
| Seattle Genetics, Inc. | $10,299 | 9 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,436 | 5 | $0 (2020) |
| Seagen Inc. | $8,470 | 6 | $0 (2023) |
| Celgene Corporation | $1,900 | 2 | $0 (2022) |
| AstraZeneca UK Limited | $1,665 | 1 | $0 (2023) |
| MorphoSys, US Inc. | $1,455 | 1 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $1,350 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,222 | 17 | PFIZER INC. ($18,997) |
| 2023 | $37,230 | 23 | BeiGene USA, Inc. ($26,310) |
| 2022 | $18,410 | 11 | BeiGene USA, Inc. ($9,855) |
| 2021 | $13,774 | 11 | BeiGene USA, Inc. ($8,250) |
| 2020 | $9,048 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($7,511) |
| 2019 | $7,129 | 6 | Seattle Genetics, Inc. ($5,204) |
| 2018 | $5,287 | 9 | Seattle Genetics, Inc. ($5,095) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $1,340.07 | General |
| 10/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $1,400.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 09/07/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $90.58 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/01/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 07/26/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,686.00 | General |
| Category: Oncology | ||||||
| 07/03/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 07/03/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Oncology | ||||||
| 12/31/2023 | Janssen Scientific Affairs, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 11/18/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 11/18/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $330.10 | General |
| Category: Oncology | ||||||
| 11/18/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $309.80 | General |
| Category: Oncology | ||||||
| 11/17/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 10/20/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 09/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $45.95 | General |
| Category: Oncology | ||||||
| 09/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $45.95 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,720 | 6 |
| ADCETRIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,160 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 2,326 | 49,219 | $2.9M | $604,440 |
| 2022 | 43 | 2,226 | 51,401 | $3.2M | $730,621 |
| 2021 | 50 | 2,513 | 61,783 | $3.8M | $987,520 |
| 2020 | 52 | 2,491 | 40,659 | $3.0M | $786,521 |
Total Patients
9,556
Total Services
203,062
Medicare Billing
$3.1M
Procedure Codes
197
All Medicare Procedures & Services
197 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 6,500 | $947,100 | $270,263 | 28.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 5,800 | $471,880 | $137,202 | 29.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 1,460 | $283,240 | $27,570 | 9.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 275 | $91,070 | $25,599 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 397 | $92,671 | $23,574 | 25.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 9,720 | $204,120 | $22,930 | 11.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 103 | 172 | $117,992 | $16,726 | 14.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 12 | 10,500 | $52,500 | $8,697 | 16.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 138 | $32,430 | $7,566 | 23.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 243 | 715 | $44,330 | $7,392 | 16.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 21 | 5,070 | $45,630 | $6,786 | 14.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 258 | 788 | $14,972 | $6,611 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 241 | 776 | $27,160 | $5,899 | 21.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $17,306 | $4,075 | 23.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 38 | $11,856 | $3,496 | 29.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 47 | 64 | $19,456 | $2,882 | 14.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 53 | $17,702 | $2,661 | 15.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 74 | 222 | $23,310 | $2,548 | 10.9% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 43 | 142 | $25,702 | $2,376 | 9.2% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 130 | 317 | $9,510 | $1,877 | 19.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 27 | 80 | $12,480 | $1,608 | 12.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 38 | 68 | $10,336 | $1,445 | 14.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 12 | 22 | $6,996 | $1,382 | 19.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 19 | $4,427 | $1,270 | 28.7% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 35 | 126 | $6,804 | $1,148 | 16.9% |
About Dr. Christopher Yasenchak, M.D
Dr. Christopher Yasenchak, M.D is a Hematology & Oncology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508830670.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Yasenchak, M.D has received a total of $114,099 in payments from pharmaceutical and medical device companies, with $23,222 received in 2024. These payments were reported across 84 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($72,436).
As a Medicare-enrolled provider, Yasenchak has provided services to 9,556 Medicare beneficiaries, totaling 203,062 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 197 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Eugene, OR
- Active Since 02/15/2006
- Last Updated 08/17/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508830670
Products in Payments
- BRUKINSA (Drug) $46,065
- ADCETRIS (Biological) $31,885
- TEVIMBRA (Drug) $1,625
- Revlimid (Drug) $1,500
- MONJUVI (Drug) $1,455
- TECVAYLI (Biological) $1,350
- Kyprolis (Biological) $125.74
- ELREXFIO (Drug) $90.58
- XGEVA (Biological) $35.33
- MYLOTARG (Biological) $20.05
- OPDIVO (Biological) $11.75
- LENVIMA (Drug) $10.81
- ELIQUIS (Drug) $9.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Eugene
Dr. Jeff Sharman, M.d, M.D
Hematology & Oncology — Payments: $745,823
Hematology & Oncology $745,823
James Butrynski, M.d, M.D
Hematology & Oncology — Payments: $22,425
Hematology & Oncology $22,425
Dr. Glenn Buchanan, Md, MD
Hematology & Oncology — Payments: $1,992
Hematology & Oncology $1,992
Dr. Jae Lee, Md, MD
Hematology & Oncology — Payments: $358.03
Hematology & Oncology $358.03
Dr. Barry Mckenzie, Md, MD
Hematology & Oncology — Payments: $281.16
Hematology & Oncology $281.16
Dr. James Fitzgibbons, Md, MD
Hematology & Oncology — Payments: $103.41
Hematology & Oncology $103.41